Striatal Binding of 11C-NMSP Studied with Positron Emission Tomography in Patients with Persistent Tardive Dyskinesia: No Evidence for Altered Dopamine D2 Receptor Binding

Overview

Journal J Neural Transm Gen Sect

Specialties Neurology
Physiology

Date 1990 Jan 1

PMID 2137000

Citations 7

Authors

U Andersson

S A Eckernas

P Hartvig

J Ulin

B Langstrom

J E Haggstrom

Affiliations

Soon will be listed here.

Abstract

Dopamine D2 receptor binding characteristics were studied by positron emission tomography (PET) using N-11C-methyl spiperone as receptor ligand in patients on longterm treatment with neuroleptic drugs and in control subjects. Eight of the patients had symptoms of tardive dyskinesia whereas three patients did not have any symptoms. Control subjects comprised 5 healthy volunteers and 7 patients with pituitary tumors. All patients had been free of neuroleptic drugs for at least 4 weeks. The time dependent regional radioactivity in the striatum was measured and the receptor binding rate, k3, proportional to receptor number, Bmax and association rate for the receptor was calculated in relation to the cerebellum. The lack in difference in k3 values between TD patients, neuroleptic treated patients without TD and control subjects throws doubt on the hypothesis that changes in striatal D2 dopamine receptor number or binding affinity is an etiological mechanism for persistent TD.

Citing Articles

Allosteric Interactions between Adenosine A and Dopamine D Receptors in Heteromeric Complexes: Biochemical and Pharmacological Characteristics, and Opportunities for PET Imaging.

Prasad K, de Vries E, Elsinga P, Dierckx R, van Waarde A Int J Mol Sci. 2021; 22(4).

PMID: 33572077 PMC: 7915359. DOI: 10.3390/ijms22041719.

Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Mahmoudi S, Levesque D, Blanchet P Mov Disord. 2014; 29(9):1125-33.

PMID: 24838395 PMC: 4807122. DOI: 10.1002/mds.25909.

Relevance of animal models to human tardive dyskinesia.

Blanchet P, Parent M, Rompre P, Levesque D Behav Brain Funct. 2012; 8:12.

PMID: 22404856 PMC: 3338072. DOI: 10.1186/1744-9081-8-12.

Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.

Lublin H, Gerlach J, Peacock L Psychopharmacology (Berl). 1993; 112(2-3):389-97.

PMID: 7871047 DOI: 10.1007/BF02244938.

Where have we got to with neuroreceptor mapping of the human brain?.

Maziere B, Maziere M Eur J Nucl Med. 1990; 16(11):817-35.

PMID: 2170141 DOI: 10.1007/BF00833018.

References

Clow A, Jenner P, Marsden C . Changes in dopamine-mediated behaviour during one year's neuroleptic administration. Eur J Pharmacol. 1979; 57(4):365-75. DOI: 10.1016/0014-2999(79)90499-0. View

Wong D, Wagner Jr H, Tune L, Dannals R, Pearlson G, Links J . Positron emission tomography reveals elevated D2 dopamine receptors in drug-naive schizophrenics. Science. 1986; 234(4783):1558-63. DOI: 10.1126/science.2878495. View

Moller Nielsen I, Fjalland B, Pedersen V, Nymark M . Pharmacology of neuroleptics upon repeated administration. Psychopharmacologia. 1974; 34(2):95-104. DOI: 10.1007/BF00421933. View

Owen F, Cross A, Waddington J, Poulter M, Gamble S, Crow T . Dopamine-mediated behaviour and 3H-spiperone binding to striatal membranes in rats after nine months haloperidol administration. Life Sci. 1980; 26(1):55-9. DOI: 10.1016/0024-3205(79)90188-7. View

Crow T, Owens D, Johnstone E, Cross A, Owen F . Does tardive dyskinesia exist?. Mod Probl Pharmacopsychiatry. 1983; 21:206-19. DOI: 10.1159/000408495. View

Clow A, Jenner P, Marsden C . An experimental model of tardive dyskinesias. Life Sci. 1978; 23(5):421-3. DOI: 10.1016/0024-3205(78)90146-7. View

Gunne L, Bachus S, Gale K . Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesias. Exp Neurol. 1988; 100(3):459-69. DOI: 10.1016/0014-4886(88)90031-3. View

Ruberg M, Bokobza B, MONTFORT J, Agid Y . [3H]spiperone binding in the nigrostriatal system in human brain. Eur J Pharmacol. 1984; 99(2-3):159-65. DOI: 10.1016/0014-2999(84)90237-1. View

Andersson U, Haggstrom J, Levin E, Bondesson U, Valverius M, Gunne L . Reduced glutamate decarboxylase activity in the subthalamic nucleus in patients with tardive dyskinesia. Mov Disord. 1989; 4(1):37-46. DOI: 10.1002/mds.870040107. View

10.

Kuhar M, Murrin L, Malouf A, Klemm N . Dopamine receptor binding in vivo: the feasibility of autoradiographic studies. Life Sci. 1978; 22(2):203-10. DOI: 10.1016/0024-3205(78)90538-6. View

11.

Burt D, Creese I, Snyder S . Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science. 1977; 196(4287):326-8. DOI: 10.1126/science.847477. View

12.

Farde L, Wiesel F, Hall H, Halldin C, Stone-Elander S, Sedvall G . No D2 receptor increase in PET study of schizophrenia. Arch Gen Psychiatry. 1987; 44(7):671-2. DOI: 10.1001/archpsyc.1987.01800190091013. View

13.

Morgan D, Marcusson J, Finch C . Contamination of serotonin-2 binding sites by an alpha-1 adrenergic component in assays with (3H)spiperone. Life Sci. 1984; 34(25):2507-14. DOI: 10.1016/0024-3205(84)90288-1. View

14.

PATLAK C, Blasberg R . Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations. J Cereb Blood Flow Metab. 1985; 5(4):584-90. DOI: 10.1038/jcbfm.1985.87. View

15.

Muhr C, Bergstrom M, Lundberg P, Bergstrom K, Hartvig P, Lundqvist H . Dopamine receptors in pituitary adenomas: PET visualization with 11C-N-methylspiperone. J Comput Assist Tomogr. 1986; 10(2):175-80. DOI: 10.1097/00004728-198603000-00001. View

16.

Crow T, Cross A, Johnstone E, Owen F, Owens D, Waddington J . Abnormal involuntary movements in schizophrenia: are they related to the disease process or its treatment? Are they associated with changes in dopamine receptors?. J Clin Psychopharmacol. 1982; 2(5):336-40. View

17.

Sedvall G, Farde L, Persson A, Wiesel F . Imaging of neurotransmitter receptors in the living human brain. Arch Gen Psychiatry. 1986; 43(10):995-1005. DOI: 10.1001/archpsyc.1986.01800100089012. View

18.

Frost J, Smith A, Kuhar M, Dannals R, Wagner Jr H . In vivo binding of 3H-N-methylspiperone to dopamine and serotonin receptors. Life Sci. 1987; 40(10):987-95. DOI: 10.1016/0024-3205(87)90321-3. View

19.

Ogren S, Hall H, Kohler C, Magnusson O, Sjostrand S . The selective dopamine D2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology (Berl). 1986; 90(3):287-94. DOI: 10.1007/BF00179179. View

20.

Clow A, Jenner P, Theodorou A, Marsden C . Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months. Nature. 1979; 278(5699):59-61. DOI: 10.1038/278059a0. View